A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

This study is testing a new antibody-drug combination (SHR-A2102) together with an immunotherapy drug (adebrelimab), with or without additional anti-cancer treatments, for people with head and neck squamous cell carcinoma (a type of throat/mouth cancer) that has returned or spread. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with advanced or metastatic head and neck squamous cell carcinoma - Your cancer has recurred or spread after prior treatment - You have measurable disease on imaging scans - You are in reasonable health and able to tolerate treatment **You may NOT be eligible if...** - You have active autoimmune disease requiring immune-suppressing treatment - You have uncontrolled infections or active hepatitis - You have had recent major surgery or radiation within a restricted timeframe - You have serious heart, liver, or lung problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.